Anti-obesity carbonic anhydrase inhibitors: challenges and opportunities

References

• Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov 2022;21:201–23.
   PubMed Web of Science ®Google Scholar
• Batchuluun B, Pinkosky SL, Steinberg GR. Lipogenesis inhibitors: therapeutic opportunities and challenges. Nat Rev Drug Discov 2022;21:283–305.
   PubMed Web of Science ®Google Scholar
• Burki T. European Commission classifies obesity as a chronic disease. Lancet Diabetes Endocrinol 2021;9:418.
   PubMed Web of Science ®Google Scholar
• de Luis D, Primo D, Izaola O, Aller R. A pilot study of gene expression analysis in peripheral blood mononuclear cells in response to a hypocaloric mediterranean diet. Dis Markers 2022;2022:3706753.
   PubMed Web of Science ®Google Scholar
• Redmond IP, Shukla AP, Aronne LJ. Use of weight loss medications in patients after bariatric surgery. Curr Obes Rep 2021;10:81–9.
   PubMed Web of Science ®Google Scholar
• Czepiel KS, Perez NP, Campoverde Reyes KJ, et al. Pharmacotherapy for the treatment of overweight and obesity in children, adolescents, and young adults in a large health system in the US. Front Endocrinol (Lausanne) 2020;11:290.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Emerging role of carbonic anhydrase inhibitors. Clin Sci 2021;135:1233–49.
   PubMed Web of Science ®Google Scholar
• De Simone G, Supuran CT. Antiobesity carbonic anhydrase inhibitors. Curr Top Med Chem 2007;7:879–84.
   PubMed Web of Science ®Google Scholar
• De Simone G, Di Fiore A, Supuran CT. Are carbonic anhydrase inhibitors suitable for obtaining antiobesity drugs? Curr Pharm Des 2008;14:655–60.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Di Fiore A, De Simone G. Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs 2008;13:383–92.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs 2012;17:11–5.
   PubMed Web of Science ®Google Scholar
• Scozzafava A, Supuran CT, Carta F. Antiobesity carbonic anhydrase inhibitors: a literature and patent review. Expert Opin Ther Pat 2013;23:725–35.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168–81.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Advances in structure-based drug discovery of carbonic anhydrase inhibitors. Expert Opin Drug Discov 2017;12:61–88.
   PubMed Web of Science ®Google Scholar
• Aspatwar A, Tolvanen MEE, Barker H, et al. Carbonic anhydrases in metazoan model organisms: molecules, mechanisms, and physiology. Physiol Rev 2022;102:1327–83.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrases and metabolism. Metabolites 2018;8:25.
   PubMed Web of Science ®Google Scholar
• a) Angeli A, Carta F, Nocentini A, et al. Carbonic anhydrase inhibitors targeting metabolism and tumor microenvironment. Metabolites 2020;10:412.
   PubMed Web of Science ®Google Scholar
  b) Nocentini A, Angeli A, Carta F, et al. Reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase. J Enzyme Inhib Med Chem 2021;36:561–80.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Experimental carbonic anhydrase inhibitors for the treatment of hypoxic tumors. J Exp Pharmacol 2020;12:603–17.
   PubMedGoogle Scholar
• Nishimori I, Vullo D, Innocenti A, et al. Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors. J Med Chem 2005;48:7860–6.
   PubMed Web of Science ®Google Scholar
• Bernardino RL, Dias TR, Moreira BP, et al. Carbonic anhydrases are involved in mitochondrial biogenesis and control the production of lactate by human Sertoli cells. Febs J 2019;286:1393–406.
   PubMed Web of Science ®Google Scholar
• Lynch CJ, Fox H, Hazen SA, et al. Role of hepatic carbonic anhydrase in de novo lipogenesis. Biochem J 1995;310:197–202.
   PubMed Web of Science ®Google Scholar
• Chegwidden WR, Spencer IM. Carbonic anhydrase provides bicarbonate for de novo lipogenesis in the locus. Comp Biochem Physiol 1996;115:247–54.
   Google Scholar
• Hazen SA, Waheed A, Sly WS, et al. Differentiation-dependent expression of CA V and the role of carbonic anhydrase isozymes in pyruvate carboxylation in adipocytes. Faseb J 1996;10:481–90.
   PubMed Web of Science ®Google Scholar
• Atwood PV. The structure and mechanism of action of pyruvate carboxylase. Int J Biochem Cell Biol 1995;27:231–49.
   PubMed Web of Science ®Google Scholar
• Alldred JB, Reilly KE. Short-term regulation of acetyl CoA carboxylase in tissues of higher animals. Prog Lipid Res 1997;35:371–85.
   Web of Science ®Google Scholar
• Arechederra RL, Waheed A, Sly WS, et al. Effect of sulfonamides as carbonic anhydrase VA and VB inhibitors on mitochondrial metabolic energy conversion. Bioorg Med Chem 2013;21:1544–8.
   PubMed Web of Science ®Google Scholar
• Antel J, Hebebrand J. Weight-reducing side effects of the antiepileptic agents topiramate and zonisamide. Handb Exp Pharmacol 2012;209:433–66.
   Google Scholar
• Alver A, Uçar F, Keha EE, et al. Effects of leptin and insulin on CA III expression in rat adipose tissue. J Enzyme Inhib Med Chem 2004;19:279–81.
   PubMed Web of Science ®Google Scholar
• Yamamoto H, Uramaru N, Kawashima A, Higuchi T. Carbonic anhydrase 3 increases during liver adipogenesis even in pre-obesity, and its inhibitors reduce liver adipose accumulation. FEBS Open Bio 2022;12:827–34.
   PubMed Web of Science ®Google Scholar
• Liu D, Wong CC, Zhou Y, et al. Squalene epoxidase induces nonalcoholic steatohepatitis via binding to carbonic anhydrase III and is a therapeutic target. Gastroenterology 2021;160:2467–82.e3.
   PubMed Web of Science ®Google Scholar
• Renner SW, Walker LM, Forsberg LJ, et al. Carbonic anhydrase III (Car3) is not required for fatty acid synthesis and does not protect against high-fat diet induced obesity in mice. PLoS One 2017;12:e0176502.
   PubMed Web of Science ®Google Scholar
• Nishimori I, Minakuchi T, Onishi S, et al. Carbonic anhydrase inhibitors. Cloning, characterization and inhibition studies of the cytosolic isozyme III with anions. J Enzyme Inhib Med Chem 2009;24:70–6.
   PubMed Web of Science ®Google Scholar
• a) Supuran CT. Exploring the multiple binding modes of inhibitors to carbonic anhydrases for novel drug discovery. Expert Opin Drug Discov 2020;15:671–86.
   PubMed Web of Science ®Google Scholar
  (b) Kumar A, Siwach K, Supuran CT, Sharma PK. A decade of tail-approach based design of selective as well as potent tumor associated carbonic anhydrase inhibitors. Bioorg Chem 2022;126:105920.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Capasso C. Antibacterial carbonic anhydrase inhibitors: an update on the recent literature. Expert Opin Ther Pat 2020;30:963–82.
   PubMed Web of Science ®Google Scholar
• Mincione F, Nocentini A, Supuran CT. Advances in the discovery of novel agents for the treatment of glaucoma. Expert Opin Drug Discov 2021;16:1209–25.
   PubMed Web of Science ®Google Scholar
• Shank RP, Gardocki JF, Vaught JL, et al. Topiramate: preclinical evaluation of structurally novel anticonvulsant. Epilepsia 1994;35:450–60.
   PubMed Web of Science ®Google Scholar
• Zareba G. Zonisamide: review of its use in epilepsy therapy. Drug Today 2005;41:589–97.
   PubMed Web of Science ®Google Scholar
• Picard F, Deshaies Y, Lalonde J, et al. Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats. Obesity Res 2000;8:656–63.
   PubMedGoogle Scholar
• Klein KM, Theisen F, Knake S, et al. Topiramate, nutrition and weight change: a prospective study. J Neurol Neurosurg Psychiatry 2008;79:590–3.
   PubMed Web of Science ®Google Scholar
• Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:1341–52.
   PubMed Web of Science ®Google Scholar
• Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012;95:297–308.
   PubMed Web of Science ®Google Scholar
• Gadde KM, Franciscy DM, Wagner HR, 2nd, Krishnan KR. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 2003;289:1820–5.
   PubMed Web of Science ®Google Scholar
• Gordon A, Price LH. Mood stabilization and weight loss with topiramate. Am J Psychiatry 1999;156:968–9.
   PubMed Web of Science ®Google Scholar
• Lévy E, Agbokou C, Ferreri F, et al. Topiramate-induced weight loss in schizophrenia: a retrospective case series study. Can J Clin Pharmacol 2007;14:e234–9.
   PubMedGoogle Scholar
• Mahmood S, Booker I, Huang J, Coleman CI. Effect of topiramate on weight gain in patients receiving atypical antipsychotic agents. J Clin Psychopharmacol 2013;33:90–4.
   PubMed Web of Science ®Google Scholar
• Schneiderhan ME, Marvin R. Is acetazolamide similar to topiramate for reversal of antipsychotic-induced weight gain? Am J Ther 2007;14:581–4.
   PubMedGoogle Scholar
• Muñoz W, Lamm A, Poppers D, Lamm S. Acetazolamide promotes decreased consumption of carbonated drinks and weight loss. Oxf Med Case Reports 2018;2018:omy081.
   PubMedGoogle Scholar
• Wallingford NM, Sinnayah P, Bymaster FP, et al. Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats. Neuropsychopharmacology 2008;33:2922–33.
   PubMed Web of Science ®Google Scholar
• Aronne LJ, Wadden TA, Peterson C, et al. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. Obesity 2013;21:2163–71.
   PubMed Web of Science ®Google Scholar
• Sari C, Seip RL, Umashanker D. Case Report: Off Label Utilization of Topiramate and Metformin in Patients With BMI ≥50 kg/m2 Prior to Bariatric Surgery. Front Endocrinol 2021;12:588016.
   PubMed Web of Science ®Google Scholar
• Casini A, Antel J, Abbate F, et al. Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV. Bioorg Med Chem Lett 2003;13:841–5.
   PubMed Web of Science ®Google Scholar
• De Simone G, Di Fiore A, Menchise V, et al. Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies. Bioorg Med Chem Lett 2005;15:2315–20.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Structure and function of carbonic anhydrases. Biochem J 2016;473:2023–32.
   PubMed Web of Science ®Google Scholar
• Supuran CT. How many carbonic anhydrase inhibition mechanisms exist? J Enzyme Inhib Med Chem 2016;31:345–60.
   PubMed Web of Science ®Google Scholar
• Alterio V, Monti SM, Truppo E, et al. The first example of a significant active site conformational rearrangement in a carbonic anhydrase-inhibitor adduct: the carbonic anhydrase I-topiramate complex. Org Biomol Chem 2010;8:3528–33.
   PubMed Web of Science ®Google Scholar
• Winum JY, Temperini C, El Cheikh K, et al. Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue. J Med Chem 2006;49:7024–31.
   PubMed Web of Science ®Google Scholar
• Vitale RM, Pedone C, Amodeo P, et al. Carbonic anhydrase inhibitors: molecular modeling study for the interaction of zonisamide and topiramate with isozyme VA. Bioorg Med Chem 2007;15:4152–8.
   PubMed Web of Science ®Google Scholar
• Davis RA, Innocenti A, Poulsen SA, Supuran CT. Carbonic anhydrase inhibitors. Identification of selective inhibitors of the human mitochondrial isozymes VA and VB over the cytosolic isozymes I and II from a natural product-based phenolic library. Bioorg Med Chem 2010;18:14–8.
   PubMed Web of Science ®Google Scholar
• Gidaro MC, Alcaro F, Carradori S, et al. Eriocitrin and Apigenin as New Carbonic Anhydrase VA Inhibitors from a Virtual Screening of Calabrian Natural Products. Planta Med 2015;81:533–40.
   PubMed Web of Science ®Google Scholar
• a) D'Ambrosio K, Carradori S, Cesa S, et al. Catechols: a new class of carbonic anhydrase inhibitors. Chem Commun (Camb) 2020;56:13033–6.
   PubMed Web of Science ®Google Scholar
  b) Mollica A, Locatelli M, Macedonio G, et al. Microwave-assisted extraction, HPLC analysis, and inhibitory effects on carbonic anhydrase I, II, VA, and VII isoforms of 14 blueberry Italian cultivars. J Enzyme Inhib Med Chem 2016;31:1–6.
   PubMed Web of Science ®Google Scholar
• Costa G, Gidaro MC, Vullo D, et al. Active Components of Essential Oils as Anti-Obesity Potential Drugs Investigated by in Silico Techniques. J Agric Food Chem 2016;64:5295–300.
   PubMed Web of Science ®Google Scholar
• Dick BL, Patel A, McCammon JA, Cohen SM. Effect of donor atom identity on metal-binding pharmacophore coordination. J Biol Inorg Chem 2017;22:605–13.
   PubMed Web of Science ®Google Scholar
• Costa G, Carta F, Ambrosio FA, et al. A computer-assisted discovery of novel potential anti-obesity compounds as selective carbonic anhydrase VA inhibitors. Eur J Med Chem 2019;181:111565.
   PubMed Web of Science ®Google Scholar
• Costa G, Artese A, Ortuso F, Alcaro S. From Homology Modeling to the Hit Identification and Drug Repurposing: A Structure-Based Approach in the Discovery of Novel Potential Anti-Obesity Compounds. Methods Mol Biol 2021;2266:263–77.
   PubMedGoogle Scholar
• Mori M, Supuran CT. Acipimox inhibits human carbonic anhydrases. J Enzyme Inhib Med Chem 2022;37:672–9.
   PubMed Web of Science ®Google Scholar
• Scozzafava A, Menabuoni L, Mincione F, et al. Carbonic anhydrase inhibitors. Synthesis of water-soluble, topically effective, intraocular pressure-lowering aromatic/heterocyclic sulfonamides containing cationic or anionic moieties: is the tail more important than the ring? J Med Chem 1999;42:2641–50.
   PubMed Web of Science ®Google Scholar
• Alterio V, Di Fiore A, D'Ambrosio K, et al. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? Chem Rev 2012;112:4421–68.
   PubMed Web of Science ®Google Scholar
• Vullo D, Franchi M, Gallori E, et al. Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides. J Med Chem 2004;47:1272–9.
   PubMed Web of Science ®Google Scholar
• Güzel O, Innocenti A, Scozzafava A, et al. Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inhibitors of human mitochondrial isoforms VA and VB. Bioorg Med Chem 2009;17:4894–9.
   PubMed Web of Science ®Google Scholar
• Smaine FZ, Pacchiano F, Rami M, et al. Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes VA and VB over the cytosolic and membrane-associated carbonic anhydrases I, II and IV. Bioorg Med Chem Lett 2008;18:6332–5.
   PubMed Web of Science ®Google Scholar
• Poli G, Bozdag M, Berrino E, et al. N-aryl-N'-ureido-O-sulfamates as potent and selective inhibitors of hCA VB over hCA VA: Deciphering the binding mode of new potential agents in mitochondrial dysfunctions. Bioorg Chem 2020;100:103896.
   PubMed Web of Science ®Google Scholar
• Maresca A, Supuran CT. (R)-/(S)-10-camphorsulfonyl-substituted aromatic/heterocyclic sulfonamides selectively inhibit mitochondrial over cytosolic carbonic anhydrases. Bioorg Med Chem Lett 2011;21:1334–7.
   PubMed Web of Science ®Google Scholar
• Poulsen SA, Wilkinson BL, Innocenti A, et al. Inhibition of human mitochondrial carbonic anhydrases VA and VB with para-(4-phenyltriazole-1-yl)-benzenesulfonamide derivatives. Bioorg Med Chem Lett 2008;18:4624–7.
   PubMed Web of Science ®Google Scholar
• Shah GN, Morofuji Y, Banks WA, Price TO. High glucose-induced mitochondrial respiration and reactive oxygen species in mouse cerebral pericytes is reversed by pharmacological inhibition of mitochondrial carbonic anhydrases: Implications for cerebral microvascular disease in diabetes. Biochem Biophys Res Commun 2013;440:354–8.
   PubMed Web of Science ®Google Scholar
• Salameh TS, Mortell WG, Logsdon AF, et al. Disruption of the hippocampal and hypothalamic blood-brain barrier in a diet-induced obese model of type II diabetes: prevention and treatment by the mitochondrial carbonic anhydrase inhibitor, topiramate. Fluids Barriers CNS 2019;16:1.
   PubMed Web of Science ®Google Scholar
• Mullard A. New hope for anti-obesity drugs. Nat Rev Drug Discov 2021;20:575.
   PubMed Web of Science ®Google Scholar